Bullish & Foolish
Full EXOZ fundamentals All 466 on the Survival Watch

EXOZEXOZYMES INC.

Is Exozymes struggling financially?

Yes, by its own account. Exozymes told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$66.4M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 8months

    If the burn speeds up

    Empty by Mar 2027

  • 12months

    If it eases off

    Empty by Jun 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.7M

÷

Cash burned over the last 12 months

$6.7M

What Exozymes told the SEC

…31, 2026 and 2025, respectively. Although the Company believes it has sufficient working capital for the near term, management believes that there remains substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and the Company’s pre-revenue status. The Company’s ability to meet its long-term liabilities and obligations depends on securing additional…

EXOZYMES INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 48% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt